Featured Research

from universities, journals, and other organizations

Angiogenesis Research May Lead To Treatments For Many Diseases, Not Just Cancer, Says U-M Expert

Date:
May 22, 1998
Source:
University Of Michigan
Summary:
With cover stories in major news magazines and reports on national news, the tumor-fighting molecules called angiogenesis inhibitors have become overnight celebrities. University of Michigan researchers are among several groups around the country trying to understand and find ways of controlling the process of angiogenesis (blood vessel growth), which plays a key role in cancer and other diseases.

ANN ARBOR---With cover stories in major news magazines and reports on national news, the tumor-fighting molecules called angiogenesis inhibitors have become overnight celebrities. University of Michigan researchers are among several groups around the country trying to understand and find ways of controlling the process of angiogenesis (blood vessel growth), which plays a key role in cancer and other diseases.

Research on this process not only may lead to improved cancer treatments, but also may offer new approaches to treating a wide range of other medical problems, says Peter Polverini, U-M professor of dentistry and pathology who has been doing research on angiogenesis for 20 years. Diabetes, rheumatoid arthritis, glaucoma, psoriasis and even obesity may someday be treated with drugs that control angiogenesis.

Most of the recent attention has focused on the potential of angiogenesis inhibitors to treat cancer by starving tumors. Tumors cannot grow to life-threatening sizes unless they are nourished by blood vessels. To ensure an adequate blood supply, tumors give off substances (angiogenic factors) that encourage nearby blood vessels to send branches to the tumors. Large tumors also give off substances (angiogenesis inhibitors) that prevent blood vessels from sending branches to smaller, more distant tumors. Researchers led by Judah Folkman at Children's Hospital in Boston have used these angiogenesis inhibitors to shrink tumors in mice.

But a number of other medical conditions also are influenced by angiogenesis and could be treated with drugs that control the process, says Polverini.

"Obviously, cancer represents the most extreme, life-threatening disease process in which blood vessel growth plays an important role, but there are many other diseases that we describe as 'angiogenesis-dependent,'" he says. "In disorders such as rheumatoid arthritis, psoriasis, and many ocular diseases---glaucoma and retinitis pigmentosa, for example---excessive blood vessel growth contributes greatly to the damage that the disease causes." Diabetes, too, has an angiogenesis link. Wounds heal more slowly in people with diabetes, because blood vessel growth is inadequate. Encouraging angiogenesis could speed healing in people with that disease.

Even melting away fat may someday be possible with help from drugs that control angiogenesis.

"There's evidence now that people who are overweight may have excessive blood vessel growth contributing to fat deposition," says Polverini. "So it's possible you could treat obesity by limiting angiogenesis."

Polverini's group is focusing on the relationship between angiogenesis and programmed cell death (apoptosis), a process that is important in normal growth and development. Jacques Nor, a doctoral student in Polverini's lab, has found that uncontrolled blood vessel growth may occur when blood vessel cells live longer than they should. Over their long life spans, these cells make blood vessels super-efficient at nourishing tumors and contributing to other disease processes. The U-M researchers' data suggest that the long-lived blood vessel cells also become resistant to substances that normally would suppress their growth and prevent them from contributing to disease.

These observations open the door to even more new approaches to treating disease by controlling blood vessel growth. For example, it may be possible to develop drugs that specifically target the cell death machinery in blood vessel cells, to suppress angiogenesis and limit solid tumor growth.

But in spite of their potential, drugs that control angiogenesis may not turn out to be the outright miracle cures that some media reports have suggested. Most likely these drugs will be used in combination with time-tested treatments such as surgery, radiation therapy and other novel anti-tumor strategies.

"As members of the armamentarium that will be used to treat tumors and other diseases, I think that they do have great promise," Polverini says. "There is every reason to believe that anti-angiogenesis will turn out to be a successful strategy for treating tumors. The only misconception about them is in setting expectations too high."


Story Source:

The above story is based on materials provided by University Of Michigan. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan. "Angiogenesis Research May Lead To Treatments For Many Diseases, Not Just Cancer, Says U-M Expert." ScienceDaily. ScienceDaily, 22 May 1998. <www.sciencedaily.com/releases/1998/05/980522082325.htm>.
University Of Michigan. (1998, May 22). Angiogenesis Research May Lead To Treatments For Many Diseases, Not Just Cancer, Says U-M Expert. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1998/05/980522082325.htm
University Of Michigan. "Angiogenesis Research May Lead To Treatments For Many Diseases, Not Just Cancer, Says U-M Expert." ScienceDaily. www.sciencedaily.com/releases/1998/05/980522082325.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins